Mick Hurrey, VP of Product Development was a speaker at the American Drug Delivery & Formulation Summit 2021 ...
Carlos Schuler, COO & CTO speaking at the 2nd Annual Inhalation and Respiratory Drug Conference on Sept 10, 2021. ...
Single Pivotal Phase 3 Trial in Atrial Fibrillation Acceptable to Support Filing of New Drug Application Company on Track to Initiate Phase 3 RESTORE1 Study in Q3 2021 with Data Expected 2H 2022 San Francisco, CA – June 23, 2021 – InCarda Therapeutics, Inc. (“InCarda”), a privately-held...
InCarda CEO Grace Colón was elected to the Board of the Biotechnology Innovation Organization “I’m honored to join the BIO board as part of the Emerging Companies Section Governing Board,” said Grace Colón. “BIO is the undisputed global leader in biotechnology education, collaboration and advocacy, and...
Positive Data from Completed InRhythm Phase 2 Study Demonstrate Safe and Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Plans to Initiate RESTORE1: Single Pivotal Phase 3 Trial in Atrial Fibrillation in Q3 2021; Data Expected 2H 2022 Appointment of Angela Wang as CFO Strengthens...
InCarda CEO Grace Colón was elected to the board of the MIT Corporation (the Institute’s board of trustees), for a five year term, effective July 1, 2021. “I am thrilled and beyond honored to share this news,” said Grace Colón. "As an MIT PhD alum, MIT...
Grace Colón participated in a three-part virtual workshop: Innovation in Drug Research and Development for Prevalent Chronic Diseases. This virtual public workshop provided a venue for stakeholders to examine bottlenecks to innovation in drug research and development (R&D) for prevalent chronic diseases and highlight opportunities...
InCarda Therapeutics CEO Grace Colón was interviewed for this brief and informative piece on Atrial Fibrillation, The Hidden Heart Problem That's Claiming Men's Lives Now by Julie Stewart in the February 2021 edition of Men’s Health. Key points: “There’s a U-shaped curve with AFib—people who don’t exercise...
Ongoing Trial to Evaluate Optimal Dose Selected from Dose-Ranging Stage of the INSTANT Study for Rapid Conversion of Atrial Fibrillation to Normal Sinus Rhythm SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular...
Our CEO Grace Colón participated in the panel "Cardiovascular and Nephrology: a Renewed Interest" at Biotech Showcase 2021 on January 11, 2021. More information below: Drug development in nephrology and cardiovascular specialties have had a revival of venture investments in recent years, after facing headwinds regarding...